As the pediatric affiliate of the NCI-designated OSUCCC-James, the BMT Program at Nationwide Children’s is connected to one of the premier adult cancer institutions in the country, thus enabling an unrivaled continuum of care.
Additionally, the BMT Program is part of numerous national and international consortia. This collaboration and reach enables the team to provide the most current therapies and opportunities for clinical trial participation. With approximately 74 percent of Nationwide Children’s eligible oncology patients enrolled in a clinical trial, Nationwide Children’s Division of Hematology, Oncology and BMT is among the leading cancer centers for clinical trial enrollment by the Children’s Oncology Group.
Active participation and leadership of BMT program faculty and staff at the local, national and international level:
- Operations Committee, Center for Regenerative Medicine and Cell-based Therapies, The Ohio State University
- Social Work Education Committee and Patient Education Advisory Group, National Marrow Donor Program (NMDP)
- American Cancer Society Central Ohio Patient Services Committee and the Central Ohio Transportation Committee
- Data Audit Committee, Foundation for the Accreditation of Cellular Therapy (FACT)-Center for International Blood and Marrow Transplant Research (CIBMTR)
- National Advisory Steering Committee, Improving Pediatric Sepsis Outcomes, Children’s Hospital Association (CHA)
- Medical Advisory Board, The Bone Marrow Foundation (BMF)
- Steering Committee, Pediatric Blood and Marrow Transplant Consortium (PBMTC)
- Supportive Care Group, PBMTC
- Cellular Therapy Group, PBMTC
- Infection and Immune Reconstitution Working Committee (INWC), Center for International Blood and Marrow Transplant Research (CIBMTR)
- Executive Committee, Pediatric Acute Lung Injury and Sepsis Initiative (PALISI) Cellular Therapies Committee, Westhafen Intercontinental Group
- NIH Recombinant DNA Advisory Committee